glp-1 trends RA prescription trends: January 2019 – December 2025 Market Overview: GLP-1 Agonists and
Description
Weight loss results will vary from individual to individual and are not guaranteed
Furthermore, diverse patient populations, encompassing individuals with various psychiatric and medical comorbidities, introduce complexities in the extrapolation of results
In particular, linagliptin might be a good choice as initial therapy in a patient with chronic kidney disease at risk for hypoglycemia
Was sagt die Wissenschaft
In terms of side effects and tolerability, the advantage goes to Semaglutide
